Euan Menzies, Chairman of Board of Directors, Named Executive Chairman and Interim CEO | President and CEO David Herron to Step Down
PRINCETON, N.J., December 20, 2019 – Bioclinica, a leading provider of clinical science and
technology expertise to assist the life science industry, today announces that David Herron,
Bioclinica’s President and Chief Executive Officer, will be leaving the company to pursue other
business interests. Euan Menzies, the Chairman of Bioclinica’s Board of Directors, will assume the
role of Executive Chairman and interim Chief Executive Officer. To ensure a seamless transition of
leadership responsibilities, Mr. Herron will remain with the Company in an advisory capacity until
the end of January 2020.
“On behalf of everyone at Bioclinica, I would like to thank David for his significant contributions to
the company,” said Menzies. “During the past several years, Bioclinica has achieved numerous
milestones, including improved financial performance and the broadening of its global presence.
We have an exceptional leadership and employee team; and are now well positioned to accelerate
the pace of investment and growth as we continue to deliver meaningful value for our clients.”
Bioclinica is an integrated clinical life science solutions provider, delivering powerful insight into clinical trial development, assuring greater client success in bringing medical therapies to market, for people around the world. Through deep medical, scientific and technology expertise, the company provides medical imaging and cardiac safety services; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site and patient payments; clinical trial management software; and drug safety solutions. Bioclinica’s global team of life science experts serve more than 500 pharmaceutical, biotechnology and device organizations – including the top 20 biopharmaceutical companies and leading CROs – through offices in North America, Europe, and Asia.